4 / 8
Pharma 2018
Page 24
E u r o p e a n C o n g r e s s o n
Pharma
A u g u s t 1 3 - 1 4 , 2 0 1 8
P a r i s , F r a n c e
American Journal of Pharmacology and Pharmacotherapeutics
ISSN: 2393-8862
T
he heart is an insulin-dependent and energy consuming organ in which
insulin and nutritional signaling integrates to the regulation of cardiac
metabolism, growth, and survival. Heart failure is highly associated with
insulin resistance and heart failure patients suffer from the cardiac energy
deficiency, structural and functional dysfunction. Recent studies demonstrated
that insulin receptor substrate-1, -2 (IRS-1, -2) are major mediators of both
insulin and insulin-like growth factor-1 (IGF-1) signaling responsible for
myocardial energetics, structure, function, and organism survival. Importantly,
the insulin receptor substrates (IRS) play an important role in activation of
the phosphatidylinositide-3 dependent kinase (PI-3K) that controls Akt and
Foxo1 signaling cascade, regulating the mitochondrial function, cardiac energy
metabolism, and the renin-angiotensin system. Dysregulation of this branch
in signaling cascades by insulin resistance in the heart through the endocrine
system promotes heart failure, providing a novel mechanism for diabetic
cardiomyopathy.
Biography
Dr. Shaodong Guo is Associate Professor with tenure the
Department of Nutrition and Food Science at Texas A&M
University College. Dr. Guo received his Ph.D in Physiology in the
Department of Biology at Peking University, China in 1995. Then
he completed his postdoctoral research training in Genetics,
Biochemistry, and Medicine in the Institute of Genetics and
Developmental Biology of Chinese Academy of Sciences,
the University of Illinois at Chicago, and Harvard University,
respectively. Dr. Guo was an Instructor in Medicine at Children’s
Hospital Boston and HarvardMedical School for two years prior
to joining the faculty at Texas A&M Health Science Center. Dr.
Guo serves as senior editor for the Journal of Endocrinology
(IF 4.7) and Journal of Molecular Endocrinology (IF 3.6), and he
is the textbook chapter writer for Metabolic Syndrome edited
by Ahima published by Springer. Dr. Guo’s research interests
include the mechanisms of diabetes, diabetic cardiomyopathy,
and the action of fuel hormones, focusing on insulin signal
transduction, insulin resistance, gene transcriptional control of
nutrient homeostasis, and cardiac dysfunction in diabetes. Dr.
Guo has been working on the gene transcriptional regulation of
metabolic homeostasis by insulin receptor substrate proteins
(IRS) and Forkhead FoxO transcription factors with the hope
of understanding how the signaling from insulin via IRS to
FoxO proteins plays a key role in many fundamental cellular
processes, including cellular growth and metabolism. His work
has been published in a number of journals including the JBC,
Endocrinology, Hypertension, Diabetes, Circulation Research,
AJP, MCB, and Nature Medicine, receiving 4,800 citations with
an h-factor of 30 based on Google Scholar Citation. Dr. Guo’s
research has been funded by American Diabetes Association
(ADA), American Heart Association, and the National Institute
of Health. He is a recipient of ADA junior faculty award, career
development award, and Research Excellence Richard R. Lee
Award.
shaodong.guo@tamu.eduTargeting the insulin receptor substrate signaling for
prevention of type 2 diabetes mellitus and heart failure
Shaodong Guo
Texas A&M University, USA
Shaodong Guo, Am J Pharmacol Pharmacother 2018, Volume 5
DOI: 10.21767/2393-8862-C1-002